Solvay earns $25M as obesity drug advances
Solvay will garner a $25 million payday from Bristol-Myers Squibb as it advances its obesity therapy, SLV319, into additional mid-stage trials. The experimental drug is a CB1 antagonist, blocking the cannabinoid type 1 receptor in order to reduce the body's demand for food.
- read the AFX report on Solvay
ALSO: Sanofi-Aventis hopes Acomplia, its anti-obesity drug, will be approved by the FDA on or around April 27, 2007. Report
Related Article:
Sanofi touts Phase IIIb Acomplia results. Report
Be the first to comment
More stories about Sanofi Aventis acomplia Bristol-Myers Squibb Solvay FDA Experimental Drugs obesity
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
